M&A Deal Summary |
|
|---|---|
| Date | 2022-10-03 |
| Target | LogicBio Therapeutics |
| Sector | Life Science |
| Buyer(s) | Alexion Pharmaceuticals |
| Deal Type | Add-on Acquisition |
| Advisor(s) | Centerview Partners (Financial) Paul, Weiss, Rifkind, Wharton & Garrison (Legal) |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1992 |
| Sector | Life Science |
| Employees | 3,082 |
| Revenue | 6.1B USD (2020) |
Alexion Pharmaceuticals is a biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with severe and life-threatening diseases that are also ultra-rare. Patients with these devastating diseases often have no effective treatment options, and they and their families suffer with little hope. Alexion Pharmaceuticals was formed in 1992 and is based in New Haven, Connecticut.
| DEAL STATS | # |
|---|---|
| Overall | 9 of 9 |
| Sector: Life Science M&A | 8 of 8 |
| Type: Add-on Acquisition M&A Deals | 9 of 9 |
| State: Massachusetts M&A | 4 of 4 |
| Country: United States M&A | 7 of 7 |
| Year: 2022 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-05-05 |
Portola Pharmaceuticals
South San Francisco, California, United States Portola Pharmaceuticals, Inc. is a biopharmaceutical company, discovers and develops therapeutics for cardiovascular and autoimmune diseases. Portola Pharmaceuticals was founded in 2003 and is based in South San Francisco, California. |
Buy | - |
